Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nereus -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (6)	8/29/2006 6:41:52 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 19

Marine actinomycetes as a source of novel secondary metabolites 2005 H. P. Fiedler;C. Bruntner;A. T. Bull;A. C. Ward;M. Goodfellow;O. Potterat;C. Puder;G. Mihm A set of 600 actinomycetes strains which were isolated from marine sediments from various sites in the Pacific and Atlantic Oceans were screened for the production of bioactive secondary metabolites. Marine streptomycete strains were found to be producers of well known chemically diverse antibiotics isolated from terrestrial streptomycetes, as in the case of marine Micromonospora strains. New marine members of the rare genus Verrucosispora seem to be a promising source for novel bioactive secondary metabolites as shown in the case of the abyssomicin producing strain AB-18-032. Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology Volume: 87 Number: 1 Well that is enough of that, ocean muck is a good place to look.